Clinical presentation of immune mediated cerebellar ataxia;Présentations cliniques et mécanismes des ataxies cérébelleuses auto-immunes

Revue Neurologique

Volumn 159, Issue 1, 2003, Pages 11-22

  Honnorat, J ^a   Trouillas, P ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; TUMOR ANTIGEN;

ANTIBODY TITER; AUTOIMMUNITY; CEREBELLAR ATAXIA; CLINICAL FEATURE; CROSS REACTION; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; PARANEOPLASTIC NEUROPATHY; PATHOGENESIS; REVIEW; TUMOR CLASSIFICATION;

ANIMALS; AUTOIMMUNE DISEASES; CEREBELLAR ATAXIA; HUMANS; PARANEOPLASTIC CEREBELLAR DEGENERATION;

EID: 0037221319     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. ABELE M, WELLER M, MESCHERIAKOV S, BÜRK K, DICHGANS J, KLOCKGETHER T. (1999). Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology, 52: 857-859.
2. AKAMATSU W, OKANO HJ, OSUMI N, et al. (1999). Mammalian Elavlike neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc Natl Acad Sci, 96: 9885-9890.
3. ALBERT ML, DARNELL JC, BENDER A, FRANSCISCO LM, BHARDWAJ N, DARNELL RB. (1998). Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Med, 11: 1321-1324.
4. ALBERT ML, AUSTIN L, DARNELL RB. (2000). Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol, 47: 9-17.
5. ANDERSON NE, CUNNINGHAM JM, POSNER JB. (1987). Autoimmune pathogenesis of paraneoplastic neurological syndromes. CRC Crit Rev Neurobiol, 3: 245-299.
6. ANDERSON NE, ROSENBLUM MK, POSNER JB. (1988a). Paraneoplastic cerebellar degeneration: clinical-immunological correlation. Ann Neurol, 24: 559-567.
7. ANDERSON NE, BUDDE-STEFFEN C, ROSENBLUM MC, GRAUS F, FORD D, SYNECK BJ, POSNER JB. (1988b). Opsoclonus, myoclonus, ataxia and encephalopathy in adults with cancer: A distinct paraneoplastic syndrome. Medecine, 67: 100-109.
8. ANTOINE JC, HONNORAT J, KOENIG F, AGUERA M, BELIN MF, MICHEL D. (1993). Posterior uvéitis and paraneoplastic encephalomyelitis with auto-antibodies reacting against cytoplasmic proteins of brain and retina. J Neurol Sci, 117: 215-223.
9. ANTOINE JC, ABSI L, HONNORAT J, et al. (1999). Anti-amphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumours. Arch Neurol, 56: 172-177.
10. ANTOINE JC, HONNORAT J, CAMDESSANCHE JP, et al. (2001). Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol, 49: 214-221.
11. BAEKKESKOV S, AANSTOOT HJ, CHRISTGAU S, et al. (1990). Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature, 347: 151-156.
12. BENYAHIA B, LIBLAU R, MERLE-BÉRAL H, TOURANI JM, DALMAU J, DELATTRE JY. (1999). Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol, 45: 162-167.
13. BORGES LF, ELLIOT PJ, GILL R, IVERSEN SD, IVERSEN LL. (1985). Selective extraction of small and large molecules from the cerebrospinal fluid by Purkinje neurons. Science, 228: 346-348.
14. BRAIN WR, DANIEL PM, GREENFIELD JG. (1951). Subacute cortical cerebellar degeneration and its relation to carcinoma. J Neurol Neurosurg Psy, 14: 59-75.
15. BRASHEAR HR, LOGIN IS, MATHE SA, PHILLIPS LH. (1997). Cerebellar disorder in stiff-man syndrome [abstract]. Neurology, 48: A433.
16. BROUWER B. (1919). Beitrag zur kenntnis der chronischen diffusen kleinhirnerkranghkungen. Neurol Centralbl, 38: 674-682.
17. BUCKANOVICH ARJ, YANG YYL, DARNELL RB. (1993). The onconeural antigen Nova-1 is a neuron RNA-binding protein and is specifically expressed in the developing motor system. Neuron, 11: 657-672.
18. BUCKANOVICH ARJ, POSNER JB, DARNELL RB. (1996). Nova, the paraneoplastic Ri antigen is homogous to an RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci, 16: 1114-1122.
19. BUCKANOVICH RJ, DARNELL RB. (1997). The neuronal RNA binding protein NOVA 1 recognizes specific RNA targets in vitro and in vivo. Mol Cell Biol, 17: 3194-3201.
20. CARPENTIER AF, ROSENFELD MR, DELATTRE JY, WHALEN RG, POSNER JB, DALMAU JO. (1998). DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res, 4: 2819-2824.
21. CHEN YT, RETTIG WJ, YENAMANDRA AK, KOZAK C, CHAGANTI RSK, POSNER JB, OLD LJ. (1990). Cerebellar degeneration related. (CDR). antigen: A highly conserved neuroectodermal marker mapped to chromosomes X in human mouse. Proc Natl Acad Sci, 87: 3077-3081.
22. CHER LM, HOCHBERG FH, TERUYA J, NITSCHKE M, VALENZUELA RF. (1995). Therapy for paraneoplastic neurological syndromes in six patients with protein A column immunoadsorption. Cancer, 75: 1678-1683.
23. CLOUSTON PD, SAPER CB, ARBIZU T, JOHNSTON I, LANG B, NEWSOMDAVIS J, POSNER JB. (1992). Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology, 42: 1944-1950.
24. DALMAU J, FURNEAUX HM, ROSENBLUM MK, GRAUS F, POSNER JB. (1991). Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis and sensory neuropathy. Neurology, 41: 1757-1764.
25. DALMAU J, GRAUS F, ROSENBLUM MK, POSNER JB. (1992). Anti-Hu associated Paraneoplastic Encephalomyelitis/Sensory neuropathy. Medicine, 71: 59-72.
26. DALMAU JO, GULTEKIN SH, VOLTZ R, et al. (1999). Ma1, a novel neuron-and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain, 122: 27-39.
27. DALMAU JO, POSNER JB. (1999). Paraneoplastic syndromes. Arch Neurol, 56: 405-408.
28. DARNELL RB, FURNEAUX HM, POSNER JB. (1991). Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical Neurons, and neuroectodermal tumors. J Neurosci, 11: 1224-1230.
29. DARNELL JC, ALBERT ML, DARNELL RB. (2000). CDR2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res, 60: 2136-2139.
30. DE LA SAYETTE V, BERTRAN F, HONNORAT J, SCHAEFFER S, IGLESIAS S, DEFER G. (1998). Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol, 55: 405-408.
31. DINKEL K, MEINCK HM, JURY KM, KARGES W, RICHTER W. (1998). Inhibition of γ-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol, 44: 194-201.
32. DROPCHO EJ, KING PH. (1994). Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: an association with type I anti-neuronal nuclear antibodies. Ann Neurol, 36: 200-205.
33. FABIAN RH, PETROFF G. (1987). Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology, 37: 1780-1784.
34. FATALLAH-SHAYKH H, WOLF S, WONG E, POSNER JB, FURNEAUX HM. (1991). Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci, 88: 3451-3454.
35. FELICIAN O, RENARD JL, VEGA F, CRÉANGE A, CHEN QM, BEQUET D, DELATTRE JY. (1995). Paraneoplastic cerebellar degeneration with anti-Yo antibody in man. Neurology, 45: 1226-1227.
36. FRITZLER MJ, KERFOOT SM, FEASBY TE, ZOCHODONE DW, WESTENDORF JM, DALMAU JO, CHAN EK. (2000). Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein-1 (MPP1). J invest Med, 48: 28-39.
37. FURNEAUX HM, REICH L, POSNER JB. (1990). Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology, 40:1085-1091.
38. GAHRING LC, ROGERS SW, TWYMAN RE. (1997). Autoantibodies to glutamate receptor subunit GluR2 in non familial olivopontocerebellar degeneration. Neurology, 48: 494-500.
39. GIOMETTO B, MIOTTO D, FARESlN F, ARGENTIERO V, SCARAVILLI T, TAVOLATO B. (1996). Anti-GABAergic neuron autoantibodies in a patient with stiff-man syndrome and ataxia. J Neurol Sci, 143: 57-59.
40. GIOMETTO B, MARCHIORI GC, NICOLAO P, SCARAVILLI T, LION A, BARDIN PG, TAVOLATO B. (1997). Subacute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol, 23: 468-474.
41. GOSHIMA Y, NAKAMURA F, STRITTMATTER P, STRITTMATTER SM. (1995). Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature, 376: 509-14.
42. GRAUS F, CORDON-CARDO C, POSNER JB. (1985). Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology, 35: 538-543.
43. GRAUS F, ILLA I, AGUSTI M, RIBALTA T, CRUZ-SANCHEZ F, JUAREZ C. (1991). Effect of intraventricular injection of anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci, 106: 82-87.
44. GRAUS F, DALMAU J, VALLDEORIOLA F, et al. (1997). Immunological characterization of a neuronal antibody. (anti-Tr). associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol, 74: 55-61.
45. GRAUS F, GULTEKIN SH, FERRER I, REIRIZ J, ALBERCH J, DALMAU J. (1998). Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol, 96: 1-7.
46. GREENBERG DA. (1997). Calcium channels in neurological disease. Ann Neurol, 42: 275-282.
47. GREENLEE JE, BRASHEAR HR. (1983). Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol, 14: 609-613.
48. GREENLEE JE, PARKS TN, JAECKLE KA. (1993). Type IIa (anti-Hu) antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology, 43: 2049-2054.
49. GREENLEE JE, BURNS JB, ROSE JW, JAECKLE KA, Clawson S. (1995). Uptake of systematically administered human anti-cerebellar antibody by rat Purkinje cells following blood brain barrier disruption. Acta Neuropathol, 89: 341-345.
50. GRIMALDI LM, MARTINO G, BRAGHI S, QUATTRINI A, FURLAN R, BOSI E, COMI G. (1993). Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol, 34: 57-64.
51. HADJIVASSILIOU M, GRÜNEWALD RA, CHATTOPADHYAY AK, et al. (1998). Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet, 352: 1582-1585.
52. HAMMACK J, KOTANIDES H, ROSENBLUM MK, POSNER JB. (1992). Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology, 42: 1938-1943.
53. HENSON RA, URICH H. (1982). Paraneoplastic disorders. In: Henson RA, Urich H, (ed) pp 311-621. Cancer and the nervous system. Blackwell Scientific Publication, Oxford.
54. HERSH B, DALMAU J, DANGOND F, GULTEKIN S, GELLER E, WEN PY. (1994). Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology, 44: 1754-1755.
55. HONNORAT J, TROUILLAS P, THIVOLET C, AGUERA M, BELIN MF. (1995). Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements. Arch Neurol, 52: 462-468.
56. HONNORAT J, ANTOINE JC, DERRINGTON E, AGUERA M, BELIN MF. (1996). Antibodies to a subpopulation of glial cells and a 66kD developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr, 61: 270-278.
57. HONNORAT J, GUILLON B, DE FERRON E, AGUERA M, ANTOINE JC, DALMAU J. (1997a). Association of anti-Neural autoantibodies in a patient with paraneoplastic cerebellar syndrome and small cell lung carcinoma. J Neurol Neurosurg Psy, 62: 425-426.
58. HONNORAT J, TRILLET M, ANTOINE JC, AGUERA M, DALMAU J, GRAUS F. (1997b). Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. J Neurol, 244: 333-339.
59. HONNORAT J, AGUERA M, ZALC B, GOUJET C, QUACH T, ANTOINE JC, BELIN MF. (1998). POP66, a paraneoplastic encephalomyelitis related antigen is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol, 57: 311-322.
60. HONNORAT J, BYK T, KUSTERS I, et al. (1999). Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci, 11: 4226-4232.
61. HONNORAT J, SAIZ A, GIOMETTO B, et al. (2001). Cerebellar ataxia with anti-Glutamic acid decarboxylase antibodies: Clinical and immunological data of a series of 14 patients. Arch Neurol, 58: 225-230.
62. HORMIGO A, DALMAU J, ROSENBLUM MK, RIVER ME, POSNER JB. (1994). Immunological and pathological study of anti-Ri associated encephalopathy. Ann Neurol 36: 896-902.
63. HORMIGO A, LIEBERMAN F. (1994). Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity. J Neuroimmunol, 55: 205-212.
64. ISHIDA K, MITOMA H, SONG SY et al. (1999). Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol, 46: 263-267.
65. ITO H, SAYAMA S, IRIE S, et al. (1994). Antineuronal antibodies in acute cerebellar ataxia following Epstein-Barr virus infection. Neurology, 44: 1506-1507.
66. JAECKLE KA, GRAUS F, HOUGHTON A, CARDON-CARDO C, NIELSEN SL, POSNER B. (1985). Autoimmune response of patients with paraneoplastic degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol, 18: 592-600.
67. JAECKLE KA, STROOP WG. (1986). Intraventricular injection of paraneoplastic anti-Purkinje cell antibody in a rat model. Neurology, 36 (Suppl. 1): 332.
68. JEAN WC, DALMAU J, HO A, POSNER JB. (1994). Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu associated paraneoplastic encephalomyelitis. Neurology, 44: 140-147.
69. JENSEN KB, DREDGE BK, STEFANI G, et al. (2000). Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron, 25: 359-371.
70. KEIME-GUIBERT F, GRAUS F, FLEURY A, RENÉ R, HONNORAT J, BROET P, DELATTRE JY. (2000). Treatment of paraneoplastic neurological syndromes with anti-neuronal antibodies (anti-Hu, anti-Yo) with a combination of Immunoglobulins, Cyclophosphamide and methylprednisolone. J Neurol Neurosurg Psy, 68: 479-482.
71. KRAKAUER J, BALMACEDA C, GLUCK JT, POSNER JB, FETELL MR, DALMAU J. (1996). Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Neurology, 46: 1486-1487.
72. LENNON VA, KRYZER TJ, GRIESMANN GE et al. (1995). Calciumchannel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med, 332: 1467-1474.
73. LUQUE FA, FURNEAUX HM, FERZIGER R, et al. (1991). Anti-Ri: an autoantibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol, 29: 241-251.
74. MALAMUD N. (1957). Atlas of neuropathology. Berkeley, CA (ed) pp 118. University of california press, San Franscisco
75. MARUSICH M, FURNEAUX H, HENION P, WESTON J. (1994). Hu neuronal proteins are expressed in proliferating neurogenic cells. J Neurobiol, 25: 143-155.
76. MASON WP, GRAUS F, LANG B, et al. (1997). Paraneoplastic cerebellar degeneration and small cell lung cancer. Brain, 120: 1279-1300.
77. MEDAWAR PB. (1948). Immunity to homologous grafted skin III. Fate of skin homografts transplanted to brain, to subcutaneous tissues and to anterior chamber of the eye. Brit J Exp Path, 29: 58.
78. MOTOMURA M, LANG B, JOHNSTON I, PALACE J, VINCENT A, NEWSOMDAVIS J. (1997). Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci, 147: 35-42.
79. OKANO HJ, PARK WY, CORRADI JP, DARNELL RB. (1999). The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev, 16: 2087-2097.
80. PANEGYRES PK, READING MC, ESIRI MM. (1993). The inflammatory reaction of paraneoplastic ganglionitis and encephalitis: an immunohistochemical study. J Neurol, 240: 93-97.
81. PELLECCHIA MT, SCALA R, FILLA A, DE MICHELE G, CIACCI C, BARONE P. (1999). Idiopathic cerebellar ataxia associated with celiac disease: lack of distinctive neurological features. J Neurol Neurosurg Psychiatry, 66: 32-35.
82. PETERSON K, ROSENBLUM MK, KOTANIDES H, POSNER JB. (1992). Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology, 42: 1931-1937.
83. PINTO A, GILLARD S, MOSS F et al. (1998). Human autoantibodies specific for the alpha 1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci, 95: 8328-8333.
84. POLYRIDES AD, OKANO HJ, YANG YY, STEFANI G, DARNELL RB. (2000). A brain-enriched polyrimidine tract-binding protein antagonizes the ability of NOVA to regulate neuron-specific alternative splicing. Proc Natl Acad Sci, 97: 6350-6355.
85. POSNER JB, FURNEAUX HM. (1990). Paraneoplastic syndromes. In: Waksman (ed). Immunologic mechanisms in neurologic and psychiatric diseases. pp 187-21. Raven Press, Ldt New York.
86. RESTITUITO S, THOMPSON RM, ELIET J, RAIKE RS, RIEDL M, CHARNET P, GOMEZ CM. (2000). The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci, 20: 6394-6403.
87. ROGEMOND V, HONNORAT J. (2000). Anti-CV2 autoantibodies and paraneoplastic neurological syndromes. Clin Rev All Immunol, 19: 48-57.
88. ROJAS I, GRAUS F, KEIME-GUIBERT F, et al. (2000). Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology, 55: 713-715.
89. RUSSELL DS. (1961). Encephalomyelitis and carcinomatous neuropathy. In: Van Bogaert L, Radermecker J, Hozay J, Lowenthal A (eds) The Encephalitides. pp 131-135 Elsevier. Amsterdam.
90. RYAN SG, BUCKWALTER MS, LYNCH JW, et al. (1994). A missence mutation in the gene encoding the alpha 1 subunit of the inhibitory glycine receptor in the spasmodic mouse. Nat Genet, 7: 131-135.
91. SAIZ A, ARPA J, SAGASTA A, CASAMITJANA R, ZARRANZ JJ, TOLOSA E, GRAUS F. (1997). Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin dependent, and polyendocrine autoimmunity. Neurology, 49: 1026-1030.
92. SAKAI K, MITCHELL DJ, TSUKAMOTO T, STEINMAN L. (1990). Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann Neurol, 28: 692-698.
93. SAKAI K, OGASAWARA T, HIROSE G, JAECKLE KA, GREENLEE JE. (1993). Analysis of autoantibody binding to 52-kd paraneoplastic cerebellar degeneration-associated antigen expressed in recombinant proteins. Ann Neurol, 33: 373-380.
94. SAKAI K, GOFUKU M, KITAGAWA Y, et al. (1994). A hippocampal protein associated with paraneoplastic neurologic syndrome and small cell lung carcinoma. Bio Biophy Res Com, 199: 1200-1208.
95. SAKAI K, GOFUKU M, KITAGAWA Y, OGASAWARA T, HIROSE G. (1995). Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52kDa paraneoplastic cerebellar degeneration associated protein. J Neuroimmunol, 60: 135-141.
96. SAUL B, SCHMIEDEN V, KLING C, MULHARDT C, GASS P, KUHSE J, BECKER CM. (1994). Point mutation of glycine receptor alpha 1 subunit in the spasmodic mouse affects agonist responses. FEBS lett, 350: 71-76.
97. SILLEVIS-SMITT PAE, MANLEY GT, POSNER JB. (1995). Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology, 45: 1873-1878.
98. SILLEVIS-SMITT P, KINOSHITA A, DE LEEUW B, et al. (2000). Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. New Engl J Med, 342: 21-27.
99. SOLIMENA M, FOLLI F, APARISI R, POZZA G, DE CAMILLI P. (1990). Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med, 322: 1555-1560.
100. SOLIMENA M, DE CAMILLI P. (1991). Autoimmunity to glutamic acid decarboxylase. (GAD). in stiff-man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci, 14: 452-457.
101. SZABO A, DALMAU J, MANLEY G, et al. (1991). HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to ELAV and sex-lethal. Cell, 67: 325-333.
102. TANAKA K, YAMAZAKI M, SATA S, TOYOSHIMA I, YAMAMOTO A, MIYATAKE T. (1986). Antibodies to brain proteins in paraneoplastic cerebellar degeneration. Neurology, 36: 1169-1172.
103. TANAKA M, TANAKA K, ONOREDA O, TSUJI S. (1995a). Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody: 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but not cause Purkinje cell loss. Clin Neurol Neurosurg, 97: 95-100.
104. TANAKA K, TANAKA M, IGARASHI S, ONOREDA O, MIYATAKE T, TSUJI S. (1995b). Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody: 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg; 97: 101-105.
105. TANAKA K, TANAKA M, INUZUKA T, NAKANO R, TSUJI S. (1999). Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuropathy with anti-Hu antibody. J Neurol Sci, 163: 159-162.
106. TELANDER RL, SMITHSON WA, GROOVER RV. (1989). Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg, 24: 11-14.
107. TROTTER JL, HENDIN BA, OSTERLAND CK. (1976). Cerebellar degeneration with Hodgkin disease. Arch Neurol, 33: 660-661.
108. VERSCHUUREN J, CHUANG L, ROSENBLUM MK, LIEBERMAN F, PRYOR A, POSNER JB, DALMAU J. (1996). Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo associated paraneoplastic cerebellar degeneration. Acta Neuropathol, 91: 519-525.
109. VOLTZ RD, POSNER JB, DALMAU J, GRAUS F. (1997). Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry, 63: 133-136.
110. VOLTZ RD, DALMAU J, POSNER JB, ROSENFELD MR. (1998). T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology, 51: 1146-1150.
111. WANG LH, STRITTMATTER SM. (1996). A family of rat CRMP genes is differentially expressed in the nervous system. J Neurosci, 16: 6197-207.
112. YANG YL, LIN YIN G, DARNELL RB. (1998). The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci, 95: 13254-13259.
113. YOON JW, YOON CS, LIM HW, et al. (1999). Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science, 284: 1183-1187.